Table 2 Number of women with a positive or negative difference in IgG levels between postpartum and delivery, and magnitude of the difference
All (n = 200) | Placenta and postpartum negative (n = 95) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
n>0 | n<0 | Difference | pa | n>0 | n<0 | Difference | pa | |||
(%) | (%) | |||||||||
All women | ||||||||||
CS2 | 115 | 85 | 5.8 | 0.054 | 57 | 38 | 6.1 | 0.033 | ||
MOZ2 | 120 | 80 | 9.8 | 0.001 | 56 | 39 | 10.0 | 0.045 | ||
By parity | ||||||||||
Primigravidae | ||||||||||
CS2 | 24 | 26 | 4.7 | 0.828 | 9 | 9 | −1.4 | 0.557 | ||
MOZ2 | 31 | 19 | 8.3 | 0.121 | 12 | 6 | 21.3 | 0.349 | ||
Secundigravidae | ||||||||||
CS2 | 20 | 17 | 0.8 | 0.886 | 9 | 7 | 3.5 | 0.351 | ||
MOZ2 | 21 | 16 | 6.7 | 0.213 | 7 | 9 | −0.1 | 0.569 | ||
Multigravidae | ||||||||||
CS2 | 71 | 42 | 13.9 | 0.015 | 39 | 22 | 18.4 | 0.023 | ||
MOZ2 | 68 | 45 | 10.4 | 0.009 | 37 | 24 | 10.0 | 0.054 | ||
By postpartum period | ||||||||||
Early | ||||||||||
CS2 | 24 | 15 | 19.1 | 0.116 | 9 | 10 | −3.5 | 0.904 | ||
MOZ2 | 22 | 17 | 17.7 | 0.357 | 8 | 11 | −0.1 | 0.658 | ||
Late | ||||||||||
CS2 | 91 | 70 | 3.3 | 0.197 | 48 | 28 | 6.9 | 0.018 | ||
MOZ2 | 98 | 63 | 8.8 | 0.002 | 48 | 28 | 12.4 | 0.015 | ||
By IPTp | ||||||||||
Placebo | ||||||||||
CS2 | 57 | 43 | 7.5 | 0.511 | 27 | 19 | 9.0 | 0.145 | ||
MOZ2 | 58 | 42 | 10.2 | 0.029 | 25 | 21 | 8.8 | 0.195 | ||
SP | ||||||||||
CS2 | 58 | 42 | 4.1 | 0.047 | 30 | 19 | 3.6 | 0.106 | ||
MOZ2 | 62 | 38 | 9.2 | 0.015 | 31 | 18 | 10.0 | 0.130 | ||
By HIV status | ||||||||||
Negative | ||||||||||
CS2 | 90 | 60 | 8.5 | 0.101 | 48 | 29 | 7.6 | 0.029 | ||
MOZ2 | 88 | 62 | 7.6 | 0.008 | 44 | 33 | 10.0 | 0.204 | ||
Positive | ||||||||||
CS2 | 25 | 25 | −1.1 | 0.527 | 9 | 9 | −1.1 | 0.879 | ||
MOZ2 | 32 | 18 | 16.7 | 0.069 | 12 | 6 | 15.9 | 0.035 | ||